ARCH Venture Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026

ARCH Venture Partners creates and backs companies built on scientific discoveries, with a healthcare focus on technologies that prevent, detect and treat disease.

The firm works through company formation as well as financing, using a network of partners to translate science into an operating business. It sizes capital to the development requirements, with investments ranging from very early commitments to hundreds of millions of dollars per company.

Its long-term model accommodates scientific programmes that need substantial development before commercial scale. Founders and researchers can engage around the creation of a company, rather than waiting until a conventional growth-stage investment case is established.

Sources
Rounds participated in
7
Confirmed lead rounds
—
7 roles undisclosed
New companies
7
First participation on record · 0 follow-on
Funding in participating rounds
$908.5M
7 disclosed · full round size, not this investor’s share

By stage

Series B3
Series A2
Undisclosed2

By primary sector

Biotech7

By country

United States6
Sweden1

Rounds

7 in this selection
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
City Therapeutics

City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.

$99.5MSeries B
Role not disclosed
Countable Labs

Develops single-molecule PCR technology for genomics measurement

$26MSeries A
Role not disclosed
CREATE Medicines

Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies

$122MSeries B
Role not disclosed
Moleculent

Decodes cellular networks to advance human health

$20MUndisclosed
Role not disclosed
Vizgen

Builds technologies for spatial biology and multi-omics innovation

$48MSeries A
Role not disclosed